Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
Nirmatrelvir plus ritonavir is effective at treating mild COVID-19 compared with standard care, as indicated by clinical evidence. However, the evidence is primarily based on studies conducted before the Omicron variant, leading to some uncertainty about its effectiveness in the current context. Sotrovimab shows likely effectiveness but with uncertain evidence, while tocilizumab is effective for severe COVID-19. The committee noted substantial uncertainty in the clinical effectiveness estimates due to the evolving nature of COVID-19 and the variants.
Cost effectiveness
Nirmatrelvir plus ritonavir is considered likely cost-effective for the highest-risk groups, with ICERs below £20,000 per QALY gained. Sotrovimab is also deemed cost-effective but only for patients for whom nirmatrelvir is contraindicated. The economic model reflects acceptable use of Healthcare resources, although some uncertainty remains regarding broader populations.
Quality of life
The document does not provide robust evidence of significant improvements in HRQoL for patients treated with nirmatrelvir plus ritonavir or other therapies. While there are indications of potential benefits, the evidence is mixed and lacks statistical significance across key domains, leading to a rating of minimal or mixed impact.
Supporting Domains
Safety and Adverse Effects
The safety profile of nirmatrelvir plus ritonavir is generally favorable, with manageable adverse events. The document indicates that adverse effects are mostly mild or moderate, with rare serious events. This suggests a very good tolerability compared to existing therapies.
Comparator Selection
The treatments were compared against appropriate standard-of-care alternatives, including nirmatrelvir plus ritonavir against standard care for mild COVID-19 and tocilizumab against standard care for severe COVID-19. The committee noted that the comparisons were relevant and aligned with current clinical practices.
Patient Population and Subgroups
The trial populations included a broad range of patients at high risk for severe COVID-19, with some subgroup analyses conducted. However, there are limitations in generalizability due to the evolving nature of the disease and the characteristics of the populations studied.
Care Pathway Integration
The integration of nirmatrelvir plus ritonavir into existing healthcare pathways is expected to be manageable, requiring only minor adjustments. The treatments fit well within current clinical practices for managing COVID-19, with no significant new infrastructure or training required.
Resource Use and Cost Implications
The budget impact of nirmatrelvir plus ritonavir is considered manageable, with potential net savings due to reduced hospitalizations. The economic model reflects a reasonable assessment of resource use, although there are concerns about the broader implications for healthcare systems.
Evidence Quality and Robustness
The evidence base includes a mix of randomized controlled trials and observational studies, but there are significant uncertainties regarding the generalizability of the results, particularly due to the changing nature of COVID-19 and the variants. This leads to a rating reflecting moderate robustness.
Uncertainty, Sensitivity, and Broader Impacts
There is considerable uncertainty regarding the effectiveness of treatments in the current endemic context, particularly with the emergence of new variants. The committee noted that while some uncertainties are manageable, they could restrict the use of treatments in certain populations.
